93MO Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial
Titel:
93MO Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial
Auteur:
Gebhart, G. Keyaerts, M. Guiot, T. Flamen, P. Ruiz Borrego, M. Stradella, A. Bermejo De Las Heras, B. Escriva de Romani, S. Calvo-Martinez, L. Ribelles Entrena, N. Martinez, N. Albacar Miro, C.R. Colleoni, M.A. Atienza de Frutos, M. Sampayo-Cordero, M. Cortés, J. Perez Garcia, J.M. Llombart Cussac, A.